Interim report Q2 2024
Business Highlights during the second quarter 2024 · Strengthened financial base with funding of DKK 27.8 million and potential of up to DKK 120 million in total. · Clinical trial application accepted by the European Medicines Agency (EMA) for the investigation of uTRACE[®] in a phase 2 trial in prostate cancer. · Second milestone payment received under the agreement with Curium Inc. using uTRACE[®] for the improved diagnosis in prostate cancer. USD 0.5 million was triggered following enrollment of the first patient in the phase 2 trial in prostate cancer. · Plans proceeding to